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To the editor:
Does SPRED1 contribute to leukemogenesis in juvenile myelomonocytic leukemia (JMML)?
Dr Pasmant and colleagues recently reported a child with a
neuro-cardio-facial-cutaneous (NCFC) syndrome caused by a germline
SPRED1 mutation.1 The child developed acute myeloid leukemia.1 The
relation between the molecular pathology of NCFC syndromes and that
of myeloid malignancies in children is well-documented. NCFC syn-
dromes include Costello, Noonan, LEOPARD, and cardiofaciocutane-
ous syndromes, neurofibromatosis type 1 (NF-1),2 and the SPRED1-
related syndrome whose phenotype closely resembles that of NF-1.3 All
of these conditions are secondary to germline mutations in genes
encoding components of the Ras mitogen–activated protein kinase
(MAPK) pathway.2 Somatic mutations in some of these genes play a
fundamental role in the pathogenesis of juvenile myelomonocytic
leukemia (JMML),4 as we and others have shown for PTPN11,5 KRAS,6
and NF1.7
SPRED1 encodes a protein that is highly expressed in hemato-
poietic cells and negatively regulates Ras-MAPK signaling by
suppressing Raf activation.8 The phenotypic similarity of the
SPRED1 syndrome to NF-1, the fact that the NF1 gene product is a
negative regulator of Ras-MAPK, the observation that children
with NF-1 are at highly increased risk of JMML, and the recent
letter by Pasmant et al1 (exemplifying a link between SPRED1
disease and myeloid leukemia in children) led us to hypothesize
that somatic mutations in SPRED1 might occur in cases of JMML
that lack mutations in other JMML-associated Ras-related genes.
To test this possibility, we sequenced the SPRED1 gene in
granulocyte DNA from 23 JMML patients without mutations in
PTPN11, KRAS/NRAS, or CBL and without an NF-1 phenotype. All
children were enrolled in the European Working Group of MDS in
Childhood (EWOG-MDS) studies 98 or 2006. Approval was obtained
from the Freiburg University institutional review board for these studies.
Informed consent was provided according to the Declaration of Hel-
sinki. The analyses comprised the entire coding sequence of SPRED1.
No mutations were discovered in the 23 JMML samples, whereas 2
known exonic synonymous single nucleotide polymorphisms, c.291
GAand c.1044 TC, were identified in all 23 cases.At position c.291
the genotype was G/A in 4 cases and A/A in 19 cases, whereas the
variation c.1044 TC showed the genotype C/T in 5 cases and C/C in
18 cases. These findings are in accordance with documented allele
frequencies in whites. We also reproduced the known intronic polymor-
phisms c.424-18 GA (G/G, 12 cases; A/A, 2 cases; A/G, 9 cases) and
c.424-8 CA (C/A, 6 cases; A/A, 17 cases). In addition, 3 known
intronic polymorphisms, c.684 49_684 50insTTAA/	, c.684
50_684  51insT/	 and c.684  53_684  54insTA/, were found
in 5 JMML specimens. In all 5 instances the variations were linked
on one allele and the other allele retained wild-type sequence.
In summary, we found no evidence of leukemogenic SPRED1
involvement in JMML cases negative for mutations in PTPN11,
KRAS/NRAS, or CBL and without NF-1 features. The assumption put
forward by Dr Pasmant and colleagues, that germline SPRED1 muta-
tions predispose children to leukemia, is certainly plausible. However,
the absence of SPRED1 mutations in an early childhood leukemia such
as JMML indicates that the putative link between SPRED1 lesions and
childhood myeloid malignancies requires further clarification.
Christiane Batz




Department of Pediatrics, Aarhus University Hospital Skejby,
Aarhus, Denmark
Eva Bergstra¨sser
Department of Pediatric Hematology-Oncology,
University Children’s Hospital,
Zu¨rich, Switzerland
Marry M. van den Heuvel-Eibrink
Department of Pediatric Oncology/Hematology,
Erasmus Medical Center and DCOG,
Rotterdam, The Netherlands
Marco Zecca
Pediatric Hematology-Oncology, University of Pavia
Fondazione IRCCS Policlinico San Matteo,
Pavia, Italy
Charlotte M. Niemeyer




Division of Pediatric Hematology-Oncology, University Medical Center,
Freiburg, Germany
on behalf of the European Working
Group of Myelodysplastic Syndromes in Childhood (EWOG-MDS)
CORRESPONDENCE 2557BLOOD, 25 MARCH 2010  VOLUME 115, NUMBER 12
 For personal use only. at UNIVERSITAETSSPITAL on March 17, 2011. www.bloodjournal.orgFrom 
Acknowledgments: Deutsche Forschungsgemeinschaft (grant KR3473/1-1
to C.F.), Deutsche Krebshilfe (grant 108220 to C.N., C.F.), and all
collaborators of the European Working Group of Myelodysplastic Syndromes
in Childhood for contributing clinical data and research material.
Conflict-of-interest disclosure: The authors declare no competing
financial interests.
Contribution: C.F. and H.H. designed the study; C.F. wrote the manuscript;
C.B. performed experiments; and H.H., E.B., M.M.v.d.H.-E., M.Z., and C.M.N.
provided samples and clinical data.
Correspondence: Christian Flotho, MD, Division of Pediatric Hematology-
Oncology, Department of Pediatric and Adolescent, Medicine, University of
Freiburg, Mathildenstr 1, 79106 Freiburg, Germany; e-mail:
christian.flotho@uniklinik-freiburg.de.
References
1. Pasmant E, Ballerini P, Lapillonne H, et al. SPRED1 disorder and predisposi-
tion to leukemia in children [letter]. Blood. 2009;114(5):1131.
2. Denayer E, de Ravel T, Legius E. Clinical and molecular aspects of RAS re-
lated disorders. J Med Genet. 2008;45(11):695-703.
3. Brems H, Chmara M, Sahbatou M, et al. Germline loss-of-function mutations in
SPRED1 cause a neurofibromatosis 1-like phenotype. Nat Genet. 2007;39(9):
1120-1126.
4. Flotho C, Kratz CP, Niemeyer CM. Targeting RAS signaling pathways in juve-
nile myelomonocytic leukemia. Curr Drug Targets. 2007;8(6):715-725.
5. Tartaglia M, Niemeyer CM, Fragale A, et al. Somatic mutations in PTPN11 in
juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute my-
eloid leukemia. Nat Genet. 2003;34(2):148-150.
6. Schubbert S, Zenker M, Rowe SL, et al. Germline KRAS mutations cause
Noonan syndrome. Nat Genet. 2006;38(3):331-336.
7. Side L, Taylor B, Cayouette M, et al. Homozygous inactivation of the NF1 gene
in bone marrow cells from children with neurofibromatosis type 1 and malignant
myeloid disorders. N Engl J Med. 1997;336(24):1713-1720.
8. Wakioka T, Sasaki A, Kato R, et al. Spred is a Sprouty-related suppressor of
Ras signalling. Nature. 2001;412(6847):647-651.
To the editor:
B cells in GVHD: friend or foe?
We were pleased to read the recent review by Shimabukuro-
Vornhagen et al, “The role of B cells in the pathogenesis of
graft-versus-host disease,” which highlights the importance of
B cells after bone marrow transplantation, as B cells have tended to
be overlooked as a contributor to transplantation immunology.1
This review comprehensively describes the use of the humanized
chimeric CD20 monoclonal antibody, rituximab, for the prophy-
laxis and treatment of acute and steroid-refractory chronic graft-
versus-host disease (GVHD).1 Three key observations have been
made: (1) the use of rituximab as part of pretransplantation
conditioning results in the in vivo depletion of donor B cells after
transplantation; (2) pretransplantation rituximab is associated with
reduced incidence and severity of acute GVHD in a cohort of
patients; and (3) elevated B-cell numbers in donor grafts are
associated with the development of both acute and chronic GVHD.
Whether B-cell depletion per se is the mechanism underlying
reduced GVHD rates, and whether this reflects a direct role of
B cells in stimulating allogeneic T-cell expansion and effector
function remains unknown.
It is important to also consider the potential nonspecific effects
of rituximab therapy on the activation of allogeneic T cells.
Nonspecific IgG treatment, such as high-dose intravenous immune
globulin, can inhibit interferon- (IFN-) responses in macro-
phages via a FcRIII-dependent mechanism, and induce natural
killer cell–mediated antibody-dependent cellular cytotoxicity of
dendritic cells (DCs).2,3 Apoptotic lymphocytes also have a regula-
tory effect upon DCs, by down-regulating costimulatory molecules
and inducing the production of the immunosuppressive cytokine
interleukin-10 (IL-10).4,5 In GVHD, these events stimulate the
generation and proliferation of regulatory T cells (Tregs), thus
suppressing allogeneic T-cell activation.
Both T and B lymphocytes play a role in tolerance induction to
autoantigens, whereby CD4 T cells regulate early allogeneic
T-cell activation and expansion, and B cells control their differen-
tiation into effector T cells.6 Host B cells have also been shown to
play a protective role in GVHD, via the secretion of IL-10 after
total body irradiation, thus inhibiting alloreactive T-cell expansion
and subsequent acute GVHD induction.7 Donor B cells can also
inhibit acute GVHD in a major histocompatibility complex class
II– and Treg-dependent manner. Mice receiving BM from B cell–
deficient mutant mice (B6.MT) developed rapid-onset acute
GVHD, contributed by faster donor CD8 T-cell engraftment and
production of IL-2 and IFN- (J.E.D., V. Watt, and D.R.S.,
manuscript in preparation), and indirect alloantigen presentation to
CD4 T cells.8 This is supported by recent in vitro human data,
indicating that activated B cells directly suppress allogeneic CD4
T-cell proliferation through the expansion of alloantigen-specific
suppressor Tregs.9
While clinical observations indicate that rituximab has a
beneficial effect in the prophylaxis of acute GVHD, it is worth
considering that an alternate mechanism of its action may exist
over and above simple B-cell depletion. Furthermore, the potential
benefit of regulatory B cells may be lost if rituximab is adopted
wholesale into pretransplantation conditioning regimens.
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